Thiolated chitosan nanoparticles enhance anti-inflammatory effects of intranasally delivered theophylline

Division of Allergy and Immunology and Joy McCann Culverhouse Airway Disease Center, Department of Internal Medicine, University of South Florida College of Medicine and James A, Haley Veteran's Hospital, Tampa, FL 33612, USA.
Respiratory research (Impact Factor: 3.38). 02/2006; 7(1):112. DOI: 10.1186/1465-9921-7-112
Source: PubMed

ABSTRACT Chitosan, a polymer derived from chitin, has been used for nasal drug delivery because of its biocompatibility, biodegradability and bioadhesiveness. Theophylline is a drug that reduces the inflammatory effects of allergic asthma but is difficult to administer at an appropriate dosage without causing adverse side effects. It was hypothesized that adsorption of theophylline to chitosan nanoparticles modified by the addition of thiol groups would improve theophylline absorption by the bronchial epithelium and enhance its anti-inflammatory effects.
We sought to develop an improved drug-delivery matrix for theophylline based on thiolated chitosan, and to investigate whether thiolated chitosan nanoparticles (TCNs) can enhance theophylline's capacity to alleviate allergic asthma.
A mouse model of allergic asthma was used to test the effects of theophylline in vivo. BALB/c mice were sensitized to ovalbumin (OVA) and OVA-challenged to produce an inflammatory allergic condition. They were then treated intranasally with theophylline alone, chitosan nanoparticles alone or theophylline adsorbed to TCNs. The effects of theophylline on cellular infiltration in bronchoalveolar lavage (BAL) fluid, histopathology of lung sections, and apoptosis of lung cells were investigated to determine the effectiveness of TCNs as a drug-delivery vehicle for theophylline.
Theophylline alone exerts a moderate anti-inflammatory effect, as evidenced by the decrease in eosinophils in BAL fluid, the reduction of bronchial damage, inhibition of mucus hypersecretion and increased apoptosis of lung cells. The effects of theophylline were significantly enhanced when the drug was delivered by TCNs.
Intranasal delivery of theophylline complexed with TCNs augmented the anti-inflammatory effects of the drug compared to theophylline administered alone in a mouse model of allergic asthma. The beneficial effects of theophylline in treating asthma may be enhanced through the use of this novel drug delivery system.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract The present study reports the preparation and physicochemical characterization of surface-modified poly(lactide-co-glycolide) (PLGA) microparticles containing interleukin-2 (rhIL-2) for pulmonary delivery. The surface of the microparticles was modified with mucoadhesive polymers such as chitosan and Carbopol 971P. The feasibility of this surface modification was confirmed by measuring the zeta potential. Chitosan-modified PLGA microparticles showed a positive zeta potential, while Carbopol-modified PLGA microparticles were negatively charged. The mucin binding efficiency values have shown that the positively charged chitosan coated microparticles showed a higher adhesive percent to the mucin than the negatively charged un-coated or Carbopol 971P coated microparticles. Furthermore, surface modification of microparticles with chitosan and Carbopol 971P has yielded a slight decrease in the amount of protein initially released. These findings suggest the suitability of surface-modified PLGA microparticles as an efficient carrier system for delivery peptides and proteins to the respiratory tract.
    Journal of Microencapsulation 04/2014; 31(4). DOI:10.3109/02652048.2013.858791 · 1.88 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Topical formulations, commonly applied for treatment of anterior eye diseases, require frequent administration due to rapid clearance from the ocular surface, typically through the lacrimal drainage system or through over-spillage onto the lids. We report on a mucoadhesive nanoparticle drug delivery system that may be used to prolong the precorneal residence time of encapsulated drugs. The nanoparticles were formed from self-assembly of block copolymers composed of poly(d, l-lactide) and Dextran. The enhanced mucoadhesion properties were achieved by surface functionalizing the nanoparticles with phenylboronic acid. The nanoparticles encapsulated up to 12 wt.% of Cyclosporine A (CycA) and sustained the release for up to five days at a clinically relevant dose, which led us to explore the therapeutic efficacy of the formulation with reduced administration frequency. By administering CycA-loaded nanoparticles to dry eye-induced mice once a week, inflammatory infiltrates were eliminated and the ocular surface completely recovered. The same once a week dosage of the nanoparticles also showed no signs of physical irritation or inflammatory responses in acute (1 week) and chronic (12 weeks) studies in healthy rabbit eyes. These findings indicate that the nanoparticles may significantly reduce the frequency of administration for effective treatment of anterior eye diseases without causing ocular irritation.
    Nano Research 02/2014; 8(2). DOI:10.1007/s12274-014-0547-3 · 6.96 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The use of nanoparticles (NPs) can improve drug delivery in many pharmaceutical applications. Compared to conventional compounds, NPs are expected to show better tissue penetration and to deliver higher drug amounts more selectively to the target site. NP-based formulations are most advanced for parenteral applications but they are also used for delivery across mucus-covered epithelial surfaces (eye, orogastrointestinal tract, airways, and vagina). The mucus layer represents an important barrier for an NP-based delivery system. In this review, mucus composition, architecture, and turnover of the mucus layer at different anatomical locations are addressed. The influence of particle parameters on mucus penetration/permeation is mentioned and examples for mucoadhesive, mucolytic, and mucus-penetrating particle systems are listed. While mucoadhesive particles have a relatively long history in NP-based drug delivery, mucus penetrating NPs have been developed more recently. These particles may be advantageous for drug delivery to anatomical sites with high mucus turnover.
    Journal of Nanoscience and Nanotechnology 01/2014; 14(1):126-36. DOI:10.1166/jnn.2014.9015 · 1.34 Impact Factor

Preview (3 Sources)

Available from